# nPlan raises $16m to expand global footprint and advance construction AI



London-based AI company nPlan has secured $16 million (£11.9 million) in a Series B funding round led by CapHorn, with participation from Chevron Technology Ventures, Suffolk Technologies, GV (Google Ventures), Pentech Ventures and LocalGlobe. The funding will support international expansion and further development of AI tools aimed at transforming capital project delivery.

nPlan uses artificial intelligence to address persistent inefficiencies in the $10 trillion global construction industry. Drawing on a dataset of more than 750,000 completed project schedules—representing over $2.5 trillion in capital investment—its platform predicts risks that could delay timelines or escalate costs. Customers have reported more than $1.2 billion in verified savings.

The scale of the problem is stark: six in seven major projects run late and about one in ten are delayed by over a year. These setbacks carry heavy economic and social costs. Traditional risk analysis tools have struggled to cope with the complexity of large projects. By contrast, nPlan’s probabilistic forecasting offers teams early warnings and evidence-based recommendations.

The company’s AI is already embedded in major programmes including HS2, Network Rail and the Transpennine Route Upgrade, where it supports possession assurance. Anglian Water uses nPlan across a portfolio of more than 1,400 projects, helping to manage a capital expansion three times larger than before. International clients include Chevron, Shell, Hong Kong’s MTR and Saudi Arabia’s NEOM development.

New tools from nPlan include Barry, an AI assistant for decision-making; Schedule Studio, which generates schedules from scope documents; and platforms such as Insights Pro and Portfolio, which support risk management and resource planning across multiple projects.

The latest funding will help nPlan grow its London headquarters and expand in North America, the Middle East and Asia-Pacific. It also aims to accelerate R&D into predictive and generative AI for infrastructure delivery. Backing from firms like Chevron and Suffolk underscores a growing belief that AI is essential for the sector’s future.

“This investment reflects pride in the UK’s leadership in construction AI and our ambition to scale globally,” said Dev Amratia, CEO and co-founder of nPlan. Flora Coppolani, Partner at CapHorn, said nPlan’s momentum and technology position it as a key player in reshaping capital delivery.

nPlan’s progress highlights how UK tech firms are using AI to tackle infrastructure’s toughest challenges—boosting productivity, reducing risk and advancing sustainable development.

Created by [Amplify](https://www.hbmadvisory.com/amplify): AI-augmented, human-curated content.

## Bibliography

1. <https://www.uktechnews.info/2025/10/17/nplan-secures-11-9-million-series-b-investment-led-by-caphorn/?utm_source=rss&utm_medium=rss&utm_campaign=nplan-secures-11-9-million-series-b-investment-led-by-caphorn> - Please view link - unable to able to access data
2. <https://www.uktechnews.info/2025/10/17/nplan-secures-11-9-million-series-b-investment-led-by-caphorn/?utm_source=rss&utm_medium=rss&utm_campaign=nplan-secures-11-9-million-series-b-investment-led-by-caphorn> - nPlan, a London-based company specialising in AI for project controls and delivery, has secured $16 million (£11.9 million) in Series B funding. The round was led by CapHorn, with participation from Chevron Technology Ventures and Suffolk Technologies, and continued support from GV (Google Ventures), Pentech Ventures, and LocalGlobe. nPlan applies advanced AI to the $10 trillion global construction industry, using a dataset of over 750,000 completed project schedules representing more than $2.5 trillion in capital spend. Their AI enables project owners and contractors to forecast and address hidden risks, improving outcomes and delivery on complex projects. To date, nPlan has saved its customers over $1.2 billion. The funding will allow nPlan to expand its London headquarters, grow its international presence, and accelerate R&D investment in predictive and generative AI for project delivery.
3. <https://www.therapixel.com/therapixel-announces-close-of-15-me-series-b-financing/> - Therapixel, a company specialising in AI solutions for mammography, has announced the completion of a €15 million Series B financing round. The funding was led by Crédit Mutuel Innovation and CapHorn, with participation from Verve Ventures, Sham Innovation Santé, and existing investors Omnes, IT-Translation, M-Capital, and Région Sud Investissement. The funds will accelerate Therapixel's commercial presence in the United States and support the launch of new features for MammoScreen®, their AI-powered mammography reading aid. MammoScreen® has received FDA regulatory clearances for both 2D and 3D mammography and is already deployed across large networks of breast cancer screening clinics.
4. <https://www.prnewswire.com/news-releases/electric-vehicle-company-harbinger-raises-100-million-in-series-b-funding-co-led-by-capricorns-technology-impact-fund-and-leitmotif-302350035.html> - Harbinger, a medium-duty electric vehicle (EV) company, has raised $100 million in Series B funding. The round was co-led by Capricorn's Technology Impact Fund and Leitmotif, with additional investments from Tiger Global and other return investors. The funds will be used to accelerate growth, increase production capacity, and expand sales, parts, and service operations for nationwide deployment. Harbinger has developed a proprietary EV stripped chassis designed for medium-duty vehicles, such as delivery vans and recreational vehicles, aiming to offer a superior EV product at price parity with traditional gasoline and diesel vehicles after federal government tax incentives.
5. <https://www.globenewswire.com/news-release/2025/09/24/3155451/0/en/Sparrow-Pharmaceuticals-Announces-95-Million-Series-B-Financing-to-Advance-Targeted-Therapy-for-Type-2-Diabetes.html> - Sparrow Pharmaceuticals, a company focused on targeted cardiometabolic therapeutics, has announced a $95 million Series B financing round. The round was co-led by RA Capital Management and Forbion, with participation from existing investors including OrbiMed, RiverVest, and US Venture Partners. The proceeds will support the development of clofutriben, a novel HSD-1 inhibitor, for the treatment of type 2 diabetes with elevated cortisol. Clofutriben is a once-daily, oral HSD-1 inhibitor that modulates intracellular cortisol production in key metabolic tissues, aiming to improve glycemic control and address a distinct patient population whose poor response to current T2D treatments is linked to excess cortisol.
6. <https://forbion.com/en/news/forbion_invests_in_capstan_therapeutics_with_participation_in_%24175m_oversubscribed_series_b_financing> - Forbion, a European life sciences venture capital firm, has participated in a $175 million oversubscribed Series B financing round in Capstan Therapeutics. The financing was led by RA Capital Management, with additional participation from new investors Johnson and Johnson Innovation, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments. Capstan is a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles. The proceeds will be used to advance CPTX2309, Capstan's lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan's tLNP pipeline.
7. <https://forbion.com/news-insights/news/forbion-co-leads-95m-series-b-in-sparrow-pharmaceuticals/> - Forbion, a European life sciences venture capital firm, has co-led a $95 million Series B financing round in Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company. The financing was co-led by Forbion and RA Capital Management, with participation from existing investors including OrbiMed, RiverVest, and US Venture Partners. The proceeds will support the development of clofutriben, a novel HSD-1 inhibitor, for the treatment of type 2 diabetes with elevated cortisol. Clofutriben is a once-daily, oral HSD-1 inhibitor that modulates intracellular cortisol production in key metabolic tissues, aiming to improve glycemic control and address a distinct patient population whose poor response to current T2D treatments is linked to excess cortisol.